Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yikang Buyuan Granule for chronic fatigue syndrome
ChiCTR1900020489Phase 4Not yet recruiting
- Sponsor
- Capital Medical University
- Start
- Dec 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Yikang Buyuan Granule in myalgic encephalomyelitis (ME), sponsored by Capital Medical University. Primary endpoint: VAS score of fatigue degree. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
Yikang Buyuan Granule
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on ChiCTR1900020489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020489.